prostate cancer

South San Francisco, California, USA, April 6, 2026 First-in-Class Epigenetic Therapy Enters Clinical Development In a major step forward...

SYDNEY, Australia, March 31, 2026 Clarity Pharmaceuticals has announced the publication of Phase II Co-PSMA clinical trial results in...

NEW YORK, March 19, 2026 Pfizer Inc. announced that its Phase 3 TALAPRO-3 clinical trial evaluating TALZENNA® (talazoparib) in...

RARITAN, N.J., February 26, 2026 Johnson & Johnson announced encouraging preliminary results from a Phase 1b clinical study evaluating...

RARITAN, N.J., February 26, 2026 Johnson & Johnson (NYSE: JNJ) announced preliminary Phase 1b clinical results demonstrating promising antitumor...

SYDNEY, Australia, Feb. 23, 2026 — Clarity Pharmaceuticals announced a significant clinical milestone in the ongoing SECuRE Trial, reporting...

Dateline: November 14, 2025 — Dublin, IrelandTrinity Biotech has announced a strategic collaboration with a leading bioinformatics partner to...

BASEL, Switzerland, Sept. 26, 2025 — Novartis announced it will present 34 abstracts from its oncology pipeline at the...